GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Debt-to-EBITDA

Third Harmonic Bio (Third Harmonic Bio) Debt-to-EBITDA : -0.10 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Third Harmonic Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.75 Mil. Third Harmonic Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.21 Mil. Third Harmonic Bio's annualized EBITDA for the quarter that ended in Dec. 2023 was $-41.57 Mil. Third Harmonic Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.10.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Third Harmonic Bio's Debt-to-EBITDA or its related term are showing as below:

THRD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.12   Med: -0.1   Max: -0.09
Current: -0.09

During the past 4 years, the highest Debt-to-EBITDA Ratio of Third Harmonic Bio was -0.09. The lowest was -0.12. And the median was -0.10.

THRD's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs THRD: -0.09

Third Harmonic Bio Debt-to-EBITDA Historical Data

The historical data trend for Third Harmonic Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Debt-to-EBITDA Chart

Third Harmonic Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- - -0.12 -0.09

Third Harmonic Bio Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.09 -0.10 -0.10 -0.10

Competitive Comparison of Third Harmonic Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Third Harmonic Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Third Harmonic Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Third Harmonic Bio's Debt-to-EBITDA falls into.



Third Harmonic Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Third Harmonic Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.745 + 3.208) / -43.919
=-0.09

Third Harmonic Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.745 + 3.208) / -41.568
=-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Third Harmonic Bio  (NAS:THRD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Third Harmonic Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Third Harmonic Bio (Third Harmonic Bio) Business Description

Traded in Other Exchanges
N/A
Address
1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111
Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Executives
Julie Person officer: Chief Administrative Officer C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner officer: Chief Medical Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139